410 related articles for article (PubMed ID: 29405496)
1. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
2. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
3. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
[TBL] [Abstract][Full Text] [Related]
4. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
5. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.
Koopman SF; Goedhart TMHJ; Bukkems LH; Mulders TM; Leebeek FWG; Fijnvandraat K; Coppens M; Mathias M; Collins PW; Tait RC; Bagot CN; Curry N; Payne J; Chowdary P; Cnossen MH; Mathôt RAA;
Br J Clin Pharmacol; 2024 Jan; 90(1):220-231. PubMed ID: 37567779
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
7. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
8. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
9. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
[TBL] [Abstract][Full Text] [Related]
10. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
[TBL] [Abstract][Full Text] [Related]
11. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
Wang M; Álvarez-Román MT; Chowdary P; Quon DV; Schafer K
Blood Coagul Fibrinolysis; 2016 Oct; 27(7):737-744. PubMed ID: 27116081
[TBL] [Abstract][Full Text] [Related]
12. The overall effectiveness of prophylaxis in severe haemophilia.
Panicker J; Warrier I; Thomas R; Lusher JM
Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517
[TBL] [Abstract][Full Text] [Related]
13. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
[TBL] [Abstract][Full Text] [Related]
14. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
16. The natural history of mild haemophilia: a 30-year single centre experience.
Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
19. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
Nilsson IM; Berntorp E; Löfqvist T; Pettersson H
J Intern Med; 1992 Jul; 232(1):25-32. PubMed ID: 1640190
[TBL] [Abstract][Full Text] [Related]
20. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
